NiKang Therapeutics is a clinical-stage biotech company developing small molecule drugs targeting HIF2α, CDK2, and KRAS to treat cancer. The company employs structure-based drug design to create precision medicines that address significant unmet medical needs in oncology.
Funding
$260M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
CAOCFounders
Product
Problem
Many cancers lack effective treatments due to the complex nature of oncogenic pathways and the difficulty in targeting specific proteins involved in tumor growth and survival. Selectively modulating these pathways to unlock the full potential of validated targets remains a significant challenge in oncology drug development.
Solution
NiKang Therapeutics is a clinical-stage biotechnology company focused on developing small molecule drugs for cancer treatment. The company utilizes disease biology insights and structure-based drug design to create precision medicines. NiKang's approach involves selectively and maximally modulating key pathways, including HIF2α, CDK2, and KRAS, to address unmet medical needs in oncology. Their strategy is modality-agnostic, creating medicines with optimal pharmacological profiles.
Target Audience
The primary target audience includes patients with cancer and healthcare providers seeking innovative treatment options, as well as pharmaceutical companies looking for novel oncology therapeutics.
Features
- Focus on small molecule drug development targeting HIF2α, CDK2, and KRAS.
- Structure-based drug design for creating precision medicines.
- Modality-agnostic approach to optimize pharmacological profiles.
- Clinical-stage pipeline with multiple drugs in Phase 1 and Phase 2 trials.
- Development of first-in-class CDK2 PROTAC degraders.
- Oral bioavailability for patient convenience.